Trial Profile
A Phase I, Open-Label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Advanced Solid and Hematologic Cancers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs CC 90002 (Primary) ; Rituximab (Primary)
- Indications Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Celgene Corporation
- 10 Aug 2021 Status changed from active, no longer recruiting to completed.
- 29 Jan 2020 Planned End Date changed from 6 Feb 2020 to 22 Feb 2021.
- 29 Jan 2020 Planned primary completion date changed from 6 Feb 2020 to 22 Feb 2021.